Headache is the most common neurological symptom and a leading cause of years lived with disability. We sought to identify the genetic variants associated with a broadly-defined headache phenotype in 223,773 subjects from the UK Biobank cohort. We defined headache based on a specific question answered by the UK Biobank participants. We performed a genome-wide association study of headache as a single entity, using 74,461 cases and 149,312 controls. We identified 3,343 SNPs which reached the genome-wide significance level of P < 5 x 10 -8 . The SNPs were located in 28 loci, with the top SNP of rs11172113 in the LRP1 gene having a P value of 4.92 x 10 -47 . Of the 28 loci, 14 have previously been associated with migraine. Among 14 new loci, rs77804065 with a P value of 5.87 x 10 -15 in the LINC02210-CRHR1 gene was the top SNP.
Introduction
Headache is the most common neurological symptom, with a life time prevalence of over 90% in the general population in the UK (1) . It represents 4.4% of consultations in primary care and 30% of outpatient consultations in neurology (2, 3) .
According to the International Headache Society, headache can be generally divided into two categories: primary headache, if not associated with another disorder; and secondary headache if associated with an underlying medical illness (4). Primary headaches mainly include migraine, tension-type, and cluster headaches. Secondary headaches include any head pain caused by infection, neoplasm, head injury, some metabolic disorders, or drugs (4).
In a comprehensive review of population-based epidemiological studies of headache, the global prevalence of recurrent headache in all ages was found to be 46% for all headaches, including 11% for migraine and 42% for tension-type headache (5). Tension-type headache is the most prevalent type of headache, whereas migraine is the most disabling (6).
Migraine affects around 6 million people in England in the age range 16-65 and it is the sixth cause in terms of years of life lost to disability according to the Global Burden of Diseases 2013 (7) . Migraine costs the National Health Service (NHS) almost £2 billion per year (8). It presents with recurrent headache attacks and/or hypersensitivity to light and sound. Around one third of migraineurs experience an aura, which are transient neurological symptoms mostly involving the visual system (9).
Family studies and twin studies have suggested that both migraine and tension-type headache are heritable traits with a heritability over 40% (10, 11) . Recently, genome-wide association studies (GWAS) have identified many genetic loci associated with migraine (12- 16) . A GWAS meta-analysis of 375,000 patients involving 22 centres has identified 38 genetic susceptibility loci for migraine with the LRP1 region in chromosome 12 being the most strongly associated (17) . Along with other GWAS on migraine, the total number of loci identified to be associated with migraine is currently 47 (18) . No GWAS have been performed for tension-type headache so far.
There are several phenotypic associations between headache and metabolic, psychological, and other factors such as obesity (19, 20) . Genome-wide association studies provide a potential route to discover genetic correlations with other complex traits and diseases that in turn may provide clues to shared genetic architectures and aetiologies (21).
To identify the genetic variants associated with headache, we conducted this GWAS using the UK Biobank cohort which has never been contributed to genetic studies of headache including migraine. We used a broadly-defined headache phenotype, the one available in the UK Biobank dataset. Secondly, we sought to test for shared genetic associations with other complex traits and diseases using linkage-disequilibrium score regression (22).
Results:

GWAS results
During the initial assessment visit (2006) (2007) (2008) (2009) (2010) , at which participants were recruited and consent was given by 501,708 UK Biobank participants, the specific pain question (see the materials and methods section for details) received 775,252 responses to all options. Among these responses, the number of participants who selected the 'Headache' option was 102,994 (cases), and the number of participants who selected the 'None of the above' option was 197,149 (controls). We further removed those whose ancestry was not white British (n = 22,694) based on principal component analysis, those who were related to one or more others in the cohort (a cut-off value of 0.025 in the generation of the genetic relationship matrix) (n = 52,166), those who were also in a Psychiatric Genomics Consortium MDD cohort (n = 597), and those who failed QC (n = 913). Thus we finally identified 74,461 cases (27,350 males and 47,111 females) and 149,312 controls (71,480 males and 77,832 females) for the GWAS association analysis. After quality control, there were 9,304,965 single nucleotide polymorphisms (SNPs) for the GWAS analysis.
The clinical characteristics of these cases and controls are summarised in Table 1 . There were statistical differences (P<0.001) in age, sex and body mass index (BMI) between cases and controls.
We identified 3,343 SNPs which reached GWAS significance of P < 5 x 10 -8 (Fig 1 , Supplementary Table S1 ). These SNPs represented 28 independent loci including 14 newlyidentified loci ( Table 2 ).
The first cluster was in the LDL receptor related protein 1 (LRP1) gene in the chromosome 12 area with a lowest P value of 4.92 x 10 -47 for rs11172113 (C allele, odds ratio (OR): 0.98).
The second cluster was in the four and a half LIM domains 5 (FHL5) gene in chromosome 6 with a lowest P value of 2.58 x 10 -31 for rs9486715 (C allele, OR: 1.02). Among the 28 loci,
In the gene set analysis by MAGMA integrated in FUMA, a total of 10,894 gene sets were tested and a default competitive test model was applied. Gene sets of positive regulation of gene expression, positive regulation of transcription from RNA polymerase ii promoter, neurogenesis, and excitatory synapse reached a P value less than 0.0001, but not statistical significant of P < 5 x 10 -6 (0.05/10,894). The top 10 gene sets from the analysis were included in Supplementary Table S3 .
In the tissue expression analysis by GTEx integrated in the FUMA, average gene-expression per tissue type was used as gene covariate to test positive relationship between gene expression in a specific tissue type and genetic associations. Two types of tissue analysis were performed. One used 30 general tissue types and the other used 53 specific tissue types. In the expression analysis of 30 general tissue types, the tissue in the brain showed the most significant P value (P = 4.12 x 10 -6 ), followed by the tissue from blood vessel (P = 0.014) ( Supplementary Table S4 ). In the 53 specific tissue types, tissues from the brain cortex reached a lowest P value of 1.44 x 10 -5 and most of the brain specific tissues also reached a significant P value of 0.001 (0.05/53). None of the vascular-related tissues reached significance. See Fig 2 and Supplementary Table S5 .
Genetic correlation analysis by LD hub
Through the genetic correlation analysis (see the materials and methods section for details), we identified multiple significant positive correlations for headache ( Supplementary Table   S6 ). The significant genetic correlations (rg) surviving multiple testing correction (P < 0.05/234) were: neuroticism (rg = 0.50, P = 2.24 x 10 -72 ), depressive symptoms (rg = 0.52, P = 1.60 x 10 -46 ), years of education (rg = -0.28, P = 5.25 x 10 -37 ), maternal age at first delivery (rg = -0.32, P = 3.97 x 10 -29 ), subjective wellbeing (rg = -0.37, P = 9.51 x 10 -19 ), insomnia (rg = 0.42, P = 2.54 x 10 -18 ), and major depressive disorder (rg = 0.39, P = 1.57 x 10 -11 ).
Discussion
We have performed a GWAS on broadly-defined headache as a single entity using the UK Biobank resource and found that variants in 28 loci were associated with having experienced headache within the last month to the extent that it interfered with usual activities. Evidence from tissue expression analysis showed that brain function is closely related to this broadlydefined headache. In addition, we found that headache was genetically correlated with a number of psychological factors, including those linked to a higher tendency toward experiencing negative emotional states, and shorter duration of education.
In this study, we defined headache cases and controls based on the responses by UK Biobank participants to a specific pain question. This question focused on headache occurrence, sufficient to cause interference with activities, during the previous month. We can therefore only treat headache as a global condition to perform GWAS. We can hypothesise, b ased on the reported population prevalence of each subtype (5,6), that tension-type headache will be the most common diagnosis among cases, followed by migraine, and that many will have experienced more than one type of headache. Whether the SNPs identified are associated with one or more of these diagnoses specifically, or with headache globally remains unclear until further research is conducted. It is important to note that half of the 28 loci were previously reported loci for migraine ( Table 2) .
The UK Biobank genetic resource is especially useful as a screening tool to test whether heterogeneous phenotypes such as headache have genetic components at all, as the UK Biobank has collected many heterogeneous phenotypes which need further genetic
investigation. An example of such a GWAS approach was adopted by Deary et al. on selfreported tiredness (a heterogeneous phenotype) using the UK Biobank cohort (23). GWAS like this will help with genetic stratification analysis for heterogeneous phenotypes. This genetic discovery phase could be part of the partitioning or classification of broadly-reported or broadly-defined headache, improving our understanding of its aetiology, diagnosis, prognosis and the development of treatments.
The findings of this research will facilitate the next essential phases of research into the genetics and causes of headache. They will enable investigators to conduct adequate power calculations for future studies and will provide candidate loci to examine in replication studies.
Even with our very heterogeneous group of cases, including many different headache subtypes, we were still able to identify numerous GWAS associations. Therefore, it can be expected that in a GWAS of a more intensively-phenotyped headache cohort or a subtype of headache such as tension-type headache for which no GWAS has yet been performed, genetic contributions could be more distinctive and easier to identify than in this study (for example, GWAS hits can be identified using fewer samples). Since our results are of GWAS significance, the genes (such as LRP1 and FHL5) identified for migraine by other GWAS are also promising candidate genes for tension-type headache. The majority of the patients with migraine (over 90%) also suffer from tension-type headache (24), and it is possible that migraine and tension-type headache might share common genetic components.
In this GWAS, we have identified 28 loci for headache. One was in the LRP1 gene with a lowest P value of 4.92 x 10 -47 for rs11172113. The LRP1 gene encodes a precursor protein that is processed by furin in the trans-Golgi complex, generating a 515 kDa alpha-chain and an 85 kDa beta-chain associated non-covalently (25). This protein is involved in multiple cellular processes, including intracellular signalling, lipid homeostasis, and clearance of apoptotic cells (26). The LRP1 gene has also been reported to be associated with and Dutch patients (15) . The locus was further replicated in Indian but not in Chinese populations (30.31). It is worth noting that many nearby supporting SNPs for the LRP1 region were located in the nearby gene of STAT6 (which was also strongly associated with headache).
The second SNP cluster was in the FHL5 gene area with a lowest P value of 2.58 x 10 -31 for rs9486715. The protein encoded by this gene is expressed with activator of cAMPresponsive element modulator (CREM) (32). It is associated with CREM and confers a powerful transcriptional activation function (32). The locus was first reported by Anttila et al to be associated with migraine (13) . Although replication failed in a Chinese population, the locus was replicated by Gormley et al in a large meta-analysis on migraine (17, 33) . Both the LRP1 and FHL5 genes are also candidate genes for cervical artery dissection suggesting vascular involvement in headache (18) . Just as the LRP1 region extends to the STAT6 gene, the FHL5 cluster extends to the UFL1 gene.
The strongest association among the 14 newly proposed loci is located in the LINC02210- 1 0
It is also interesting to note that the STAT6 gene was the most significant in the gene analysis with headache and not the LRP1 gene where the top SNP resides. These two genes are next to each other in the genome and have previously been associated with disorders related to the immune system such as food allergen sensitization and Sjogren's Disease (39, 40) . It is reported that IL4/STAT6 signalling activates neural stem cell proliferation and neurogenesis in zebrafish brain, which indicates the importance of the gene in neuron function (41) . The gene sets analysis revealed that genes involved in the neurogenesis are associated with headache which is consistent with the tissue expression analysis.
Both tissue expression analysis on 30 general tissue types and 53 specific tissue types showed significant associations between brain tissues and headache, but not vascular tissues. This conclusion is different from the predominant theory of vascular aetiology for migraine since our results suggest that brain function is closely related to broadly-defined headache. Combining all results from GWAS and FUMA together, it is clear that both neuronal and vascular factors are involved in the headache mechanism.
Consistent with previous studies from our group, we found strong evidence to support a shared genetic aetiology of pain with psychological traits, indicating a vulnerability to depression and other negative mood states (42, 43) . In addition, we found a negative correlation with factors associated with a longer duration of education. Previous results have suggested that headache sufferers were more likely to have psychiatric disorders than healthy people (44). In addition, a shared genetic link between migraine and depression has been identified (45). Further studies are needed to demonstrate the nature of these correlations and whether any directional 'causal' inferences can be drawn.
The Q-Q plot suggested that there are residual confounding factors between headache cases and controls which have not been adjusted for. Those could be factors associated with psychiatric and vascular disorders. We also noted the is a 90 degree upswing (around 1 the P = 10 -14 level). This is due to the fact that we have a cluster of 1,800 significant SNPs at this level (mainly located at the LINC02210-CRHR1-MAPT loci), which is over half of the total number of significant SNPs.
Using the CaTS power calculator, we had 80% power to identify SNP associations with a significance level of 5 x 10 -8 , based on 74,461 cases and 149,312 controls, assuming an additive model, a minor disease allele frequency of 0.15, a genotypic relative risk of 1.05, and a prevalence of headache in the general population of 0.2 (a conservative assumption) (46).
In conclusion, we have identified 28 loci for broadly-defined headache as a single entity in a GWAS using the UK Biobank resource, including 14 loci that have previously been associated with migraine, and 14 loci that have not previously been associated with headache. This is the largest GWAS on headache in a single population so far. We also identified evidence that brain function is closely related to broadly-defined headache. In addition, we found several significant correlations with a number of psychological factors, suggesting that the genetic aetiology of headache may also be related to these traits.
Materials and Methods
Participants and genetic information of participants
The UK Biobank is a health research resource that aims to improve the prevention, 
Phenotypic information on pain
The UK Biobank participants were offered a pain-related questionnaire, which included the question: 'in the last month have you experienced any of the following that interfered with your usual activities?'. The options were: The headache cases in this study were those who selected the 'Headache' option for the above question, regardless of whether they had selected other options.
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The controls in this study were those who selected the 'None of the above' option.
Statistical analysis
Standard Frequentist association tests using BGENIE was used to perform association studies adjusting for age, sex, BMI, 9 population principal components, genotyping arrays, and assessment centres. Gender difference between cases and controls was compared using chi-square testing. Age and BMI were compared using independent t testing in IBM SPSS 22 (IBM Corporation, New York). SNP associations were considered significant if they had a P value less than 5 x 10 -8 .
SNP functional annotations were applied by the FUMA web application and a Manhattan plot was generated by R (48). R was also used to generate the corresponding Q-Q plot, a tool to evaluate differences between cases and controls caused by potential confounders.
The gene analysis and gene-set analysis were performed with MAGMA v1.6, which was integrated in FUMA (49). Both analyses were based on GWAS summary statistics. In gene analysis, summary statistics of SNPs are aggregated to the level of whole genes, testing the joint association of all SNPs in the gene with the phenotype. In gene-set analysis, individual genes are aggregated to groups of genes sharing certain biological, functional or other characteristics. This will provide insight into the involvement of specific biological pathways or cellular functions in the genetic aetiology of a phenotype. Tissue expression analysis was obtained from GTEx (https://www.gtexportal.org/home/) which was also integrated in FUMA.
In order to identify genetic correlations with other complex traits and diseases, we used linkage disequilibrium score regression through LD Hub v1 
